Free Newsletter
Emergent accuses biotech execs of wrecking buyout pact
Rockville, MD-based Emergent BioSolutions has filed suit against Protein Sciences, saying the vaccine developer never planned to follow through on a planned $75 million acquisition agreement. According to Emergent's claim, the top executives of Protein Sciences ridiculed the deal after it was announced and only really wanted $10 million in bridge financing that came with the pact so it could pursue other options. Protein Sciences' Daniel D. Adams and Manon M.J. Cox were singled out in the lawsuit.
"I'm very surprised and disappointed by the actions of Emergent," Cox told the Washington Post. "The way things are going, perhaps it's better in principle if the companies go their own ways."
Protein Sciences is in the final stages of the approval process for its FluBlock vaccine, which is grown in insect cells rather than the traditional egg-based manufacturing approach.
- read the article in the Washington Post
Related Articles:
Emergent adds new space for biotech start-ups
Emergent buys Protein Sciences in $75M deal
Emergent BioSolutions files $86M IPO
Comments
Post new comment
Paid Research Reports
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
- Innovative Drug Discovery in Emerging Markets
- Market Opportunities for Supergenerics
- The Future of In Vitro and In Vivo Diagnostic Integration
SHARE
WITH: